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TNF-aAbstract Introduction: The production of cytokines, growth factors and adhesion molecules pro-
motes tumor progression and involves inflammation, angiogenesis and thrombosis, thus providing
optimal conditions for cancer development.
Materials and methods: The present study was undertaken to evaluate association of cytokine
gene polymorphisms with cervical cancer in a north Indian population. Genotyping of single
nucleotide polymorphisms (SNPs) viz. IL-6-597G/A (rs1800797), IL-1b-511C/T (rs16944) and
TNF-a-308G/A (rs1800629) was carried out in 100 each of cases and healthy age matched controls
by polymerase chain reaction–restriction fragment length polymorphism (PCR–RFLP). Genotype
and allele frequencies were calculated by SPSS (ver.16) and gene–gene interaction was analyzed
using SHEsis (ver. Online).
Results: Epidemiological studies showed that women >40 years have higher risk of cervical can-
cer due to early pregnancies. IL-6 and TNF-a promoter polymorphisms showed significant associ-
ation (P< 0.001) while the SNP combinations G A T* and G G T* of IL-6-597A/G, TNF-a-308G/
A and IL-1b-511C/T polymorphisms showed increased risk up to 9.0 and 3.30 times respectively.
Conclusion: Therefore, the promoter polymorphisms in cytokine genes can be used as biomark-
ers to predict cervical cancer susceptibility in a north Indian population. However, such studies
need to be carried out in different ethnic populations in order to discover the specific risk alleles,
genotypes and combinations for disease prediction.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Ain Shams University. This is
an open access article under theCCBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cervical cancer is the second most common cancer in women
worldwide with 5,30,000 new cases every year. A mortality
of 2,70,000 cases and 5-year prevalence of 1,547,161 wasreported in 2013 [1]. The highest incidence is found in develop-
ing countries out of which 25% is from India.
Epidemiological and clinical data show that the develop-
ment of cervical cancer is a multifactorial process in which
infection with human papillomavirus (HPV) takes a central
place along with other risk factors such as smoking, immuno-
suppression, immunodeficiency, diet, parity, age at first full-
term pregnancy and family history [2].
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thrombosis are involved which strongly correlate with immune
cells residing in the microenvironment of cancerous tissues.
Immune cells are involved in the production of cytokines
(pro- and anti-inflammatory), growth factors and adhesion
molecules which promote tumor progression by a signaling
cascade and provide optimal growth conditions for cancerous
cells. A number of previous reports suggested that chronic
inflammation is associated with precancerous intraepithelial
lesion and cervical cancer [3]. IL-6 acts as a defense mechanism
at acute inflammatory levels but during chronic inflammation
it behaves like a pro-inflammatory cytokine involved in
immune regulation [4,5], hematopoiesis [6,7] and oncogenesis
thereby inducing acute phase responses [8]. During chronic
inflammation, IL-6 also favors mononuclear monocyte chemoat-
tractant protein (MCP-1) secretion, angio-proliferation and anti-
apoptotic functions on T cells. It is expressed by a wide variety
of different cell types including keratinocytes of the uterine cer-
vix [9]. A promoter SNP-597 (A/G) in IL-6 gene located on
chromosome 7p21 [10] is a susceptibility factor in many
diseases like coronary heart disease, breast cancer, cervical
cancer etc [11].
Cytokine family interleukin-1 (pro-inflammatory) consists
of several members including interleukin-1beta (IL-1b) and
interleukin-1receptor antagonist (IL-1RN) which are compo-
nents of innate immune system as well as chronic inflamma-
tion. IL-1b is a pro-inflammatory cytokine produced by
blood monocytes and tissue macrophages which regulate the
expression of several molecules involved in inflammation. IL-
1b acts synergistically with chemical carcinogens resulting in
proliferation of mutated cells and further accumulation of
genetic defects. IL-1RN inhibits the activities of IL-1b by com-
petitively binding to IL-1b receptor and modulating a variety
of interleukin-1 related immune and inflammatory responses
[12–15].
Tumor necrosis factor alpha (TNF-a) is another potential
pro-inflammatory cytokine and plays a role in inflammation
and malignant diseases [16]. TNF-a gene located on chromo-
some 6 between HLA class I and II regions (within the major
histocompatibility complex, MHC) activates the positive cell
cycle regulator NF-jB resulting in proliferation of cells, inva-
sion and finally metastasis [17,18]. A single nucleotide poly-
morphism (SNP) in the promoter region of TNF-a gene
associated with its regulation and expression may contribute
to the pathogenesis and promote malignant progression of cer-
vical cancer. In the present study, the association of genetic
polymorphisms in IL-6, IL-1b and TNF-a genes was studied
in cervical cancer patients from north India.
2. Subjects and methods
2.1. Patient selection and sample collection
Our study included cervical cancer patients (n= 100) and
normal control subjects (n= 100) enrolled in the outpatient
unit of Department of Obstetrics and Gynecology, King
George’s Medical University, Lucknow, India. The study was
conducted after due approval of Institutional Ethics Committee
(No. 4135/R.Cell-13, dated 15/4/2013) andwritten consent from
all subjects. The work has been carried out in accordance
with The Code of Ethics of the World Medical Association(Declaration of Helsinki) for experiments in humans. After
selection, subjects were counseled and cervical biopsy was con-
ducted by expert gynecologists and sent for histopathological
examination. Clinical details of patients and other risk factors
viz. smoking status, parity, abortion, and use of contraception
were precisely recorded. Blood samples (2 ml) from all study
subjects were collected in EDTAvials and stored at20 Cuntil
further use. The inclusion/exclusion criteria for cases and
controls are given below:
Inclusion criteria for cases:
 Histopathologically proven cases of squamous cell carci-
noma (SCC) all stages and cervical intraepithelial neoplasia
(CIN).
 Women between 40 and 70 year with cervical cancer symp-
toms such as vaginal discharge, pain in lower abdomen,
menstrual irregularity and contact bleeding.
 Positive cervical biopsy.
Exclusion criteria for cases:
 Women >70 years.
 Cases having double malignancy.
 Cases having any co-morbid conditions such as diabetes,
tuberculosis etc.
 Negative cervical biopsy.
 Cases already on follow-up.
 Not willing to participate.
Inclusion criteria for control subjects:
 Healthy age matched.
 Histopathologically negative for all stages of squamous cell
carcinoma (SCC) and cervical intraepithelial neoplasia
(CIN).
 No previous history of any type of cancer.
2.2. DNA extraction and genotyping
Genomic DNA was extracted from peripheral blood mononu-
clear cells (PBMCs) using salting out method [19] with slight
modifications [20]. Genotyping of three polymorphisms
IL-6-597A/G (rs1800797), IL-1b-511C/T (rs16944) and TNF-
a-308G/A (rs1800629) were performed by Polymerase Chain
Reaction-Restriction Fragment Length Polymorphism (PCR–
RFLP). The primers designed by Primer 3.0 online software
were F-50-GGAGTCACACACTCCACCT-30/R-50-CTGATT
GGAAACCTTATTAAG-3 0;F-5 0-AGGCAATAGGTTT
TGAGGGCCAT-30/R-50-TTGGGGACACAAGCATCAAG
G-30 and F-50-TGGCATTGATCTGGTTCATC-30/R-50-GTT
TAGGAATCTTCCCACTT-30 respectively. The 15 ll reaction
mixture contained 100 ng of template DNA, buffer (100
mMTris, pH 9.0; 500 mMKCl; 15 mM MgCl2; 0.1% gelatin),
200 lM dNTP, 10 pmol of each primer and 1.0 unit Taq DNA
polymerase (Biosciences, India). The PCR products of IL-6,
TNF-a and IL-1b were digested with FokI, NcoI and SacI
restriction enzymes respectively (Thermo Fisher Scientific Inc.,
USA), electrophoresed on 12.5% polyacrylamide gels (Sisco
Research Laboratories Pvt. Ltd., India), stained with EtBr
(Sisco Research Laboratories Pvt. Ltd., India) and documented
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results were cross checked randomly in order to confirm our
methodology.
2.3. Statistical analysis
Allele frequencies and carriage rates of alleles in all groups
were compared in a 2  2 contingency table and genotype fre-
quencies in a 2  3 contingency table using Chi square test (v2)
and Fisher’s exact t-test. Hardy–Weinberg equilibrium at
individual locus was assessed by v2 statistics using Statistical
Package for Social Science (SPSS) version 16.0. All P values
were two-sided and differences were considered statistically
significant for P< 0.05. Odds Ratio (OR) at 95% confidenceTable 1 Effect of socio demographic characteristics on
cervical cancer.
Demographic
Profile
Controls
(n= 100) (%)
Cases
(n= 100) (%)
v2 p-value
Age (in Years)
640 22(22.0) 20(20.0) 0.121 0.729
>40 78(78.0) 80(80.0)
Place of residence
Rural 80(80.0) 88(88.0) 2.381 0.123
Urban 20(20.0) 12(12.0)
Educational status
Illiterate 40(40.0) 56(56.0) 5.128 0.024#
Literate 60(60.0) 44(44.0)
Socio-economic status
Lower 40(40.0) 52(52.0) 4.520 0.104
Middle 50(50.0) 44(44.0)
Upper 10(10.0) 04(04.0)
Personal history
(A) Parity
None 08(08.0) 01(01.0) 22.752 <0.001#
62 68(68.0) 44(44.0)
>2 24(24.0) 55(55.0)
(B) Age at first full term pregnancy
P20 84(84.0) 60(60.0) 14.286 <0.001#
<20 16(16.0) 40(40.0)
(C) Menstrual cycle
Irregular 68(68.0) 42(42.0) 13.657 <0.001#
Regular 32(32.0) 58(58.0)
(D) Menstrual hygiene
Cloths 28(28.0) 59(59.0) 19.551 <0.001#
Napkins 72(72.0) 41(41.0)
Reuse of cloths
No 21(75.0) 22(37.3) 10.803 <0.001#
Yes 07(25.0) 37(62.7)
(E) Use of contraception
Oral
contraceptive
pills
19(19.0) 11(11.0) 12.723 0.005#
Condoms 23(23.0) 14(14.0)
Others 16(16.0) 08(08.0)
None 42(42.0) 67(67.0)
Smoker
Active smoker 21(21.0) 38(38.0) 6.948 0.008#
Passive smoker 79(79.0) 62(62.0)
HR-HPV
Positive 36(36.0) 86(86.0) 52.543 <0.001#
Negative 64(64.0) 14(14.0)
v2 Chi-square, #implies significant at 5% level.
Bold denotes significant p values.intervals (CI) was determined to describe the strength of asso-
ciation by Logistic Regression Model. The associations of cer-
vical cancer risk factors and gene polymorphisms with cervical
cancer were evaluated by Logistic Regression Model (domi-
nant model). All statistical analyses were carried out using
SPSS software, version 16.0.
2.4. Gene–gene interaction analysis
Gene–gene interaction and pairwise linkage disequilibrium
(LD) based on ‘D’ statistics and correlation coefficient (r2) of
frequencies were analyzed using SHEsis [21].
3. Results
A large number of women in the age group >40 years showed
a higher incidence of cervical cancer as compared to the lower
age group (640 year) which was evident from demographic
data (Table 1). Risk factors viz. higher parity, lower age at first
full term pregnancy, irregular menstrual cycle, menstrual
hygiene, no contraception showed significant relation with cer-
vical cancer. A significant correlation with smoking as well as
high risk human papillomavirus (HR-HPV) incidence was
observed in cases (p< 0.001) (Table 1).
Controls and cervical cancer cases (histopathologically
proven) were successfully genotyped for IL-6-597A/G, IL-1b-
511C/T and TNF-a-308G/A polymorphisms (Fig. 1). The
allele and genotype frequency distributions as well as carriage
rates are shown in Table 2. All allelic and genotypic frequen-
cies were found to be in Hardy–Weinberg equilibrium
(HWE). In IL-6-597A/G polymorphism, ‘GG’ (25%) and
‘AG’ (40%) genotype frequencies in cases were found to be
higher in comparison to controls showing significant difference
(p< 0.001) (Table 2). Moreover, the prevalence of -597*G
allele was significantly higher in cases (45.0%, p< 0.001) withFigure 1 Polyacrylamide gels (12%) stained with EtBr showing
genotypes of different gene polymorphisms. (A) IL-6-597A/G
genotypes; M, pBR322/HaeIII. (B) TNF-a-308G/A genotypes; M,
pUC19/MspI. (C) IL-1b-511C/T genotypes; M, pUC19/MspI.
UD, Undigested. Markers obtained from Biosciences, India.
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showed that the presence of -597*G allele of IL-6-597A/G
increases the risk of cervical cancer in our population up to
6.2 times (p< 0.001) (Table 2). Although the frequency of
cases with ‘TT’ genotype (57% vs 47%) and -511*T allele
(88%) was higher in comparison to controls, the IL-1b-
511C/T polymorphism did not show significant association
(Table 2).
TNF-a-308G/A polymorphism showed a higher ‘AA’ geno-
type frequency in cases (30%) in comparison to controls (9%)
and significant difference (P< 0.001). The prevalence of -
308*A allele in cases was higher in comparison to controls
(63% vs 53%) with an OR of 1.5 and showed significant asso-
ciation with cervical cancer (p< 0.043) (Table 2).
In order to examine the role of risk factors in cervical can-
cer, we stratified the analysis of effects of IL-6, IL-1b and
TNF-a polymorphisms on cervical cancer according to variousTable 2 Genotypic, allelic and carriage rate frequencies of IL-6-597
healthy controls (n= 100) and cervical cancer cases (n= 100).
Genotype frequency Number (%frequency)
IL-6 AA AG
Controls 77 (77.0) 20 (20.
Cases 35 (35.0) 40 (40.
IL-1b CC CT
Controls 2 (2) 51 (51)
Cases 1 (1) 42 (42)
TNF-a GG GA
Controls 3 (3) 88 (88)
Cases 4 (4) 66 (66)
Allele frequency Number (%frequency)
IL-6 A G
Controls 174 (87.0) 26 (13.
Cases 110 (55.0) 90 (45.
IL-1b C T
Controls 55 (27.5) 145 (72
Cases 44 (22) 156 (88
TNF-a G A
Controls 94 (47) 106 (53
Cases 74 (37) 126 (63
Carriage rate IL-6 A (+) A ()
Controls 97 (97.0) 3 (3.0)
Cases 75 (75.0) 25 (25.
G (+) G ()
Controls 23 (23.0) 77 (77.
Cases 65 (65.0) 35 (35.
IL-1b C (+) C ()
Controls 53 (53) 47 (47)
Cases 43 (43) 67 (67)
T (+) T ()
Controls 98 (98) 2 (2)
Cases 99 (99) 1 (1)
TNF-a G (+) G ()
Controls 91 (91) 9 (9)
Cases 70 (70) 30 (30)
A (+) A ()
Controls 97 (97) 3 (3)
Cases 96 (96) 4 (4)
v2 Chi-square, 95%CI = confidence interval, OR = Odds Ratio, #implie
Bold denotes significant p values.risk factors. The effect of IL-6-597A/G polymorphism on the
risk of cervical cancer showing significant association included
high parity (p< 0.001), lower age at full term pregnancy
(p< 0.001), irregular menstrual cycle (p< 0.001), menstrual
hygiene (p< 0.001) and smoking (p< 0.001) (Table 3). Simi-
lar result was also observed in the case of IL-1b gene polymor-
phism with positive HR-HPV infection status (p< 0.001) and
active smoking (p< 0.001) (Table 4). The association of TNF-
a with various risk factors such as high parity, lower age at of
first full term pregnancy, irregular menstrual cycle and hygiene
were found to be significant (p< 0.001) in cases of cervical
carcinoma (Table 5).
Gene-gene interaction analysis showed that individuals
with the SNP combinations G A T* and G G T* of IL-6-
597A/G, TNF-a-308G/A and IL-1b-511C/T polymorphisms
have an increased risk of cervical cancer up to 9.0 and 3.3 times
respectively in the study population (Fig. 2).A/G, TNF-a-308G/A and IL-1b-511C/T gene polymorphisms in
v2 p-value
GG 39.702 <0.001#
0) 3 (3.0)
0) 25 (25.0)
TT 2.166 0.339
47 (47)
57 (57)
AA 35.485 <0.001#
9 (9)
30 (30)
p-value Odds Ratio (OR) 95% CI
0) <0.001# 5.476 3.330-9.004
0)
.5) 0.203 1.345 0.852-2.123
)
) 0.043# 1.510 1.013-2.251
)
<0.001# 0.093 0.027-0.319
0)
0) <0.001# 6.217 3.341-11.570
0)
0.158 0.669 0.383-1.168
0.568 2.020 0.180-22.645
<0.001# 0.231 0.103-0.517
0.701 0.742 0.162-3.405
s significant at 5% level.
Table 3 Association between cervical cancer risk factors and IL-6-597A/G gene polymorphism.
IL-6–597A/G Controls (n= 100) Cases (n= 100) p-value OR, (95% C.I)
AA (n= 77) AG (n= 20) + GG (n= 3) AA (n= 35) AG (n= 40) + GG (n= 25)
Parity
None 5 3 00 1 .999 5.3  108 (.00)
62 55 13 20 24 <0.001# 5.07 (2.17–11.84)
>2 17 7 15 40 0.001# 6.47 (2.24–18.72)
Age at first full term pregnancy
P20 45 15 27 57 <0.001 10.22 (4.95–21.10
<20 32 8 8 8 0.030# 4.0 (1.45–13.95)
Menstrual cycle
Regular 52 15 18 24 <0.001# 4.62 (1.99–10.69)
Irregular 9 7 17 41 0.051 3.10 (0.994–1.412)
Menstrual hygiene
Cloths 23 5 17 42 <0.001# 11.36 (3.71–34.80)
Napkins 54 18 18 23 0.001# 3.83 (1.69–8.66)
Reuse of cloths
No 12 4 9 18 0.011# 6.0 (1.50–23.99)
Yes 11 1 8 24 0.002# 33.0 (3.66–297.2)
Use of contraception
OCP 12 8 4 7 0.213 2.62 (0.574–11.99)
Condoms 16 7 0 8 0.998 1.84 * 109 (0.00)
Others 8 8 9 5 0.433 0.556 (0.128–2.41)
None 41 0 22 45 0.997 3 * 109 (0.00)
Smoking
Smoker 12 9 4 34 <0.001# 11.33 (2.94–43.68)
Non-smoker 65 14 31 31 <0.001# 4.64 (2.16–9.95)
HR-HPV infection status
Positive 20 16 28 58 0.433 0.55 (0.128–2.41)
Negative 37 7 7 7 0.014# 5.28 (1.40–19.84)
95% CI = confidence interval, OR= Odds Ratio, #implies significant at 5% level.
Bold denotes significant p values.
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Risk factors for cervical cancer showed that the development
of cancer is a multifactorial process in which infection with
high risk human papillomavirus (HR-HPV) takes a central
place in the development of cervical cancer. However, HPV
infection is not the only cause of cervical cancer but other risk
cofactors have been identified including oral contraceptive use,
smoking, immunosuppression, immunodeficiency, diet, parity,
age at the first full-term pregnancy and family history of cervi-
cal cancer. In the present study, it was found that women of
age >40 years have higher incidence of cervical cancer as com-
pared to the age group 640 years. This might be due to the fact
that during adolescence (15–19 years) cervical epithelium is
more susceptible to HPV; therefore, early age (<40 years) of
sexual intercourse and subsequent pregnancy become risk fac-
tors for cervical cancer [22]. It has been reported that the dis-
ease progression takes 10–15 years to manifest. Therefore,
cases with HPV infection and subjected to other risk factors
show the disease beyond 40 years of age [23]. It was also found
that females getting pregnant at <20 years of age with more
than two children are more susceptible to cervical cancer and
showed significant correlation (p< 0.001). Poor menstrual
hygiene such as use of homemade sanitary napkins and their
reuse after washing were found to be independent risk predic-
tors for cervical cancer in women. This factor was linked to
low socio-economic conditions since the majority of the studypopulation was illiterate and belonged to low economic strata
in rural areas, and therefore showed higher frequency of cervi-
cal cancer.
Functional DNA polymorphisms which alter the expres-
sion of inflammatory molecules play a decisive role at different
stages of tumor development including pathogenesis, invasion
and metastasis. HPV infection and inflammation during cervi-
cal cancer are critical components in progression of the dis-
ease. During HPV infection, cytokine genes responsible for
inflammation are regarded as a potential source of cervical
cancer risk. Inflammation involves extensive tissue remodeling
events which are orchestrated by complex networks of cytoki-
nes, chemokines and bio-active lipids working across multiple
cellular compartments to maintain tissue homeostasis. Only 5–
10% of all cancers are caused by inheritance of mutated genes
and somatic mutations, whereas the remaining 90–95% have
been linked to lifestyle factors and environment [24].
In neoplastic diseases, circulating levels of IL-6 increase
markedly during development and progression of tumors.
Polymorphisms in IL-6 gene are reported as susceptibility fac-
tors in several diseases such as multiple myeloma [25], rheuma-
toid arthritis [4], Castleman’s disease [26], AIDS [27,28],
mesangial proliferative glomerulonephritis [29], psoriasis [30],
Kaposi’s sarcoma [31], sepsis [32], osteoporosis [33,28] and cer-
vical cancer [11]. The association of IL-6-597A/G polymor-
phism with cervical cancer in the study population showed
that the prevalence of IL-6-597*G allele was significantly
Table 4 Association between cervical cancer risk factors and IL-1b-511C/T gene polymorphism.
IL-1b-511C/T Controls (n= 100) Cases (n= 100) p-value OR, 95%CI
CC (n= 2) + CT (n= 51) TT (n= 47) CC (n= 1) + CT (n= 42) TT (n= 57)
Parity
None 7 1 1 0 1.00 000(00)
62 32 36 16 28 0.265 1.55 (0.715–3.384)
>2 14 10 26 29 0.367 1.562 (0.593–4.115)
Age at first full term pregnancy
P20 34 26 36 48 0.103 1.744 (0.893–3.404)
<20 19 21 7 9 0.799 1.163 (0.362–3.735)
Menstrual cycle
Regular 36 32 15 27 0.080 2.025 (0.918–4.465)
Irregular 17 15 28 30 0.660 1.214 (0.512–2.882)
Menstrual hygiene
Cloths 14 31 15 27 0.649 0.813 (0.333–1.985)
Napkins 39 16 27 30 0.012# 2.708(1.241–5.910)
Reuse of cloths
No 4 3 17 10 0.778 0.784 (0.145–4.244)
Yes 8 13 12 19 0.964 0.974 (0.312–3.044)
Use of contraception
OCP 14 6 6 5 0.392 1.944 (0.423–8.928)
Condoms 16 7 3 5 0.120 3.810(0.707–20.533)
Others 10 6 4 10 0.069 4.167 (0.894–19.419)
None 13 28 30 37 0.180 0.573 (0.253–1.294)
Smoking
Smoker 16 5 16 22 0.015# 4.400(1.335–14.506)
Non-smoker 37 42 27 35 0.697 1.142(0.585–2.229)
HR-HPV infection status
Positive 27 9 37 49 0.002# 3.973 (1.670–9.453)
Negative 26 38 6 8 0.878 0.112 (0.283–2.940)
95% CI = confidence interval, OR= Odds Ratio, #implies significant at 5% level.
Bold denotes significant p values.
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also showed that promoter polymorphism in IL-6 gene in
combination with -308*A allele of TNF-a and -511*T allele
of IL-1b genetic variants increases the risk of cervical cancer
up to 9.0 times in the present study (Fig. 2). The association
between IL-6 promoter polymorphism and cancer risk was evi-
dent among Asians and Africans but not Caucasians [34].
Other IL-6 SNPs like -174G/C polymorphism has been associ-
ated with an increased risk of breast cancer [35,36], leukemia
[37], colorectal cancer [38] and basal cell cancer [39].
The IL-1b polymorphism was not found to be associated
with the risk of cervical cancer in the study population. There
are previous reports which suggest that IL-1b may be involved
in early steps of cervical carcinoma development and progres-
sion [40,14]. Increased levels of IL-1b reduce apoptosis by
changing the ratio of BCL-2/BAX protein and increased p53
mutation which leads to DNA damage in epithelial cells of
the cervix [41]. Various epidemiologic risk factors of cervical
cancer as positive HR-HPV infection status and active smok-
ing are associated with IL-1b in the present study. However,
it can be validated further by increasing the sample size of
the study.
In our study, TNF-a polymorphism showed a significant
association with various risk factors and cervical carcinomas
while previous studies observed the same in Caucasian ethnic
groups but not Asians [42]. In the present study -308*A allelewas higher in cases (63%) with an OR of 1.5 which was earlier
shown in Portuguese population with an OR of 1.8 [43]. The
women carrying TNF-a-308*A allele were seen to have an
increased disease risk up to 2 folds. In contrast, the South
African population showed no association of TNF-a -308G/
A polymorphism and risk of cervical cancer [44]. The differ-
ence between these polymorphisms may be due to the variation
of ethnic groups, showed sample size, patient recruitment
standards and geographical or environmental factors. The pre-
sent study supports a potential role of genetic variations in the
TNF-a promoter region in susceptibility to cervical cancer.
The results obtained from our study are consistent with sev-
eral previous studies [15,45–47] but similar genotyping analysis
in other ethnic populations are still necessary to validate the
association between SNPs and susceptibility to cervical cancer.
SNP studies show a considerable level of variation among
various ethnic populations around the world. Therefore, it is
essential to perform association studies/SNP analyses in indi-
vidual populations so that they can be benefitted. Individuals
at risk will be able to take prior precautionary measures and
avoid or delay the onset of disease. The challenge for the future
will be to understand the genotypic interactions between SNPs
in the same gene or genes at different loci. Recent data impli-
cate that cytokine gene polymorphisms are important in the
pathogenesis of various neoplastic and non-neoplastic human
diseases.
                Case(freq)  Control(freq)   Chi2   Fisher's p             Pearson's p  Odds Ratio [95%CI] 
A A C* 10.75(0.054) 33.90(0.170) 13.500  0.000241 0.000240  0.278 [0.136~0.570] 
A A T* 64.46(0.322) 55.44(0.277) 0.977  0.322880 0.322820  1.241 [0.808~1.906] 
A G C* 14.73(0.074) 10.38(0.052) 0.807  0.369182 0.369134               1.453 [0.640~3.298] 
A G T* 21.06(0.105) 72.28(0.361) 36.625  1.54e-009 1.47e-009 0.208 [0.122~0.356] 
G A C* 18.40(0.092) 11.72(0.059) 1.609  0.204752 0.204673  1.629 [0.762~3.486] 
G A T* 37.39(0.187) 4.94(0.025) 27.839  1.37e-007 1.35e-007 9.084 [3.474~23.748] 
G G T* 33.09(0.165) 11.34(0.057) 11.990  0.000539 0.000538  3.300 [1.629~6.684] 
Figure 2 Haploview of SNPs viz. of IL-6-597A/G, TNF-a-308G/A and IL-1b-511C/T showing association with cervical cancer in a
north Indian population. Pairwise linkage disequilibrium (LD) (SHEsis, ver. Online). 95%CI = confidence interval. * indicates allele
combination of IL-6-597A/G, TNF-a-308G/A and IL-1b-511C/T gene polymorphisms.
Table 5 Association between cervical cancer risk factors and TNF-a-308G/A gene polymorphism.
TNF-a-308G/A Controls (n= 100) Cases (n= 100) p-value OR, 95%CI
GG (n= 3) + GA (n= 88) AA (n= 9) GG (n= 4) + GA (n= 66) AA (n= 30)
Parity
None 6 2 1 0 0.999 00(00)
62 62 6 30 14 0.003# 4.822 (1.686–13.794)
>2 23 1 39 16 0.035# 9.436 (1.173–75.905)
Age at first full term pregnancy
P20 55 5 63 21 0.014# 3.667 (1.296–10.376)
<20 36 4 7 9 0.001# 11.571 (2.771–48.316)
Menstrual cycle
Regular 65 3 28 14 <0.001# 10.833 (2.884–40.684)
Irregular 26 6 42 16 0.353 1.651 (0.573–4.756)
Menstrual hygiene
Cloths 27 1 44 15 0.036# 9.205 (1.150–73.691)
Napkins 64 8 26 15 0.002# 4.615 (1.747–12.195)
Reuse of cloths
No 19 1 18 5 0.146 5.278 (0.561–49.662)
Yes 8 0 26 10 0.999 4.971  108(00)
Use of contraception
OCP 18 1 9 2 0.283 4.00 (0.319–50.220)
Condoms 18 5 7 1 0.574 0.514 (0.051–5.221)
Others 14 2 11 3 0.517 1.909 (0.270–13.490)
None 40 1 43 24 0.003# 22.326 (2.885–172.763)
Smoking
Smoker 17 4 29 9 0.681 1.319 (0.352–4.943)
Non-smoker 74 5 41 21 <0.001# 7.580 (2.660–21.604)
HR-HPV
Positive 31 5 63 23 0.130 2.263 (0.785–6.523)
Negative 60 4 7 7 <0.001# 15.00 (3.495–64.376)
95% CI = confidence interval, OR= Odds Ratio, #implies significant at 5% level.
Bold denotes significant p values.
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